Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
natural killer cells
Biotech
CEO invests own cash to move NKGen toward Alzheimer’s readout
Song invested $2.65 million of his own money in NKGen to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial.
Nick Paul Taylor
May 8, 2025 10:22am
Innate antibody pits NK cells against lymphoma in animal models
Nov 15, 2024 2:00pm
MD Anderson launches cell therapy institute with $80M
Nov 11, 2024 4:20pm
Artiva plans IPO to fund NK cell therapy's autoimmune trials
Jul 1, 2024 7:48am
Synthekine hopes new IL-2 will be the high-alpha in a beta class
Apr 10, 2024 9:50am
Nkarta's blood cancer CAR stalls again, driving deprioritization
Mar 22, 2024 9:11am
